Why AstraZeneca May Be 2025's Most Underrated Pharma Stock
In 2025, AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises. So, revenue from Enhertu, which is a highly effective HER2-di...
3 Promising Growth Stocks You Can Buy for Less Than $100
Investing in growth stocks is a great way to grow your portfolio in the long run. But it can be difficult to predict which ones will take off in value and which one's won't.
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-nee...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrat...
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cance...
AstraZeneca's Breztri meets main goals of late-stage asthma trials
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
AstraZeneca has plenty coming down the pipeline to appease the bears
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that ...
AstraZeneca PLC (AZN) Q1 2025 Earnings Conference Call Transcript
AstraZeneca PLC (NASDAQ:AZN ) Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ET Company Participants Andy Barnett - Head of IR Pascal Soriot - Executive Director and CEO Aradhana Sarin - E...
AstraZeneca shares claw their way back into green after revenue miss
After an early stumble, AstraZeneca PLC (LSE:AZN) shares pulled back to level by the close on Tuesday, but analysts see reasons for investors to stay watchful despite the apparent strength of the r...
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.
AstraZeneca shares fall 4% after Q1 revenue miss
Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance ...
AstraZeneca says may face further import tax fine from China
AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of $1.6 million, adding that a fine of one to five times that amount may be...
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Astrazeneca (AZN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates fo...
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation mode...
AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment
AstraZeneca PLC (LSE:AZN) reported notable progress in ongoing trials of patients with metastatic breast cancer using a combination of drugs, Enhertu and pertuzumab. Enhertu, jointly developed by t...
Related Companies